Podcasts

Rafael Fonseca, MD, discusses the steps that large cancer centers should take to protect their patients as well as staff from COVID-19 infection, specific measures that Mayo Clinic has taken for developing in-house testing, and more.

Chadi welcomes back Emily Landon, MD, to provide updates on issues of state-funded COVID-19 testing and laboratory resources, the importance of social distancing and isolation to limit the strain on local health systems, and more.

David Mitchell, president and founder of Patients for Affordable Drugs, discusses the need for an entity to recommend costs for novel therapies to payers, pieces of legislation that address drug patent "abuse" on the part of manufacturers,...

Emily Landon, MD, executive medical director of infection prevention and control, University of Chicago, breaks down current exposure risk and mortality rates of COVID-19, preventative steps to avoid exposure, and promising therapies on the...

Rafael Fonseca, MD, and Saurabh Jha, MD, debate the benefits and disadvantages of a third-party vs single payer system and whether Medicare has been a successful program for qualifying patients.

Sayeh Nikpay, PhD, MPH, Vanderbilt University School of Medicine, explains the origins of 340B, how safety net clinics as well as large hospitals became participants in the program, and the possibility of getting rid of the program...

Neeraj Agarwal, MD, discusses management decisions for patients with advanced or metastatic prostate cancer, including weariness in using ADT for many patients with comorbidities and how clinicians are currently weighing existing regimens.

Daniel Goldstein, MD, Rabin Medical Center (Israel), discusses the ability of interventional pharmacoeconomics to lower drug costs and increase access around the world, as well as the dilemma physicians face for treating patients with a...

John Mandrola, MD, explains how all medical evidence is flawed and a critical mistake HCPs can make with overgeneralizing the results of clinical trials.

Stacie Dusetzina, PhD, Vanderbilt University School of Medicine, discusses the "desensitization" of society to cancer prescription drug costs and solutions proposed by politicians for inflated Medicare Part D spending, among other topics.